Please login to the form below

Not currently logged in


This page shows the latest Sandoz news and features for those working in and with pharma, biotech and healthcare.

Novartis buys cancer specialist Endocyte for $2.1bn

psoriasis drug Cosentyx (secukinumab) and Entresto (sacubitril/valsartan) for heart failure – up 37% to $750m and 113% to $271m, respectively – as well as Sandoz’biosimilar drugs.

Latest news

More from news
Approximately 18 fully matching, plus 189 partially matching documents found.

Latest Intelligence

  • Building a bright future Building a bright future

    Mylan’s biosimilar of the multiple sclerosis injection therapy copaxane is not gliding to the promised land, and delays have given rivals Momenta and Novartis’Sandoz a tilt at the

  • Deal Watch November 2016 Deal Watch November 2016

    In May this year Sandoz announced that a regulatory submission for its version of rituximab had been accepted by the EMA following multiple clinical trials in over 800 patients.

  • Deal Watch October 2016 Deal Watch October 2016

    Even without non-exclusive deals from one supplier, there is the additional competitive risk of new biosimilar entrants, such as Sandoz, etcetera.

  • Can biosimilars live up to the hype? Can biosimilars live up to the hype?

    There are a lot of things to be very proud of in Europe,” says Carol, who is also global head biopharmaceuticals and oncology injectables at Sandoz. “ ... More than 700 biosimilars are being developed around the world with Sandoz on target for ten

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    The biosimilars under development by companies such as Sandoz, Amgen and Boehringer-Ingelheim may not be an immediate threat but together they have the potential to severely impact the company's ... Having long lagged behind its European counterparts,

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 18 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...